Merck's Tulisokibart Met Primary and Key Secondary Endpoints in Phase 2b Study in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)
Business Wire•30/09/2026•08:15 ET
0
Key Highlights
- ➤High-dose tulisokibart achieved 72% HiSCR50 response at week 16, versus 35% placebo
- ➤Medium-dose tulisokibart achieved 64% HiSCR50 response at week 16, versus 35% placebo
- ➤High-dose tulisokibart achieved 41% HiSCR75 response, versus 15% placebo
- ➤Merck (MRK) plans to advance tulisokibart into Phase 3 HS development
- ➤Tulisokibart safety was comparable with placebo in the Phase 2b trial
Expert Statements
Alexa B. Kimball, Lead investigator, President and CEO of Harvard Medical Faculty Physicians at Beth Israel Deaconess Medical Center, and Professor of Dermatology at Harvard Medical School
“Results from the MK-7240-012 trial are promising and suggest the potential for meaningful improvement in the management of this difficult-to-treat condition.”
Aileen Pangan, Vice President and Therapeutic Area Head, Immunology Clinical Research, Merck Research Laboratories
“We look forward to advancing tulisokibart to Phase 3 for patients living with HS.”
Merck's Tulisokibart Met Primary and Key Secondary Endpoints in Phase 2b Study in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)
Results mark the first positive Phase 2 data for an anti-TL1A monoclonal antibody in dermatology
Get started
Create a free account to read the full story.